The HFSA Virtual Heart Failure Patient and Caregiver Day 2020 is LIVE NOW!
2019 | HFSA

Clinical Trial Results from MyoKardia’s Phase 2 PIONEER-HCM Study of Mavacamten Published in the Annals of Internal Medicine

Practice News Industry

Mavacamten is Being Developed to Treat the Most Common Inherited Form of Heart Disease, Hypertrophic Cardiomyopathy, for which no targeted medical therapies exist.

A Twelve-week Treatment with Mavacamten Demonstrated Reductions in Obstruction and Improvements in Patient Symptoms and Function.
 

MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced the publication of results from the company’s Phase 2 PIONEER-HCM study of mavacamten in an upcoming issue of the Annals of Internal Medicine. A copy of the article, “Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy” is now available online at  Annals of Internal Medicine.

Learnings from Phase 2 Trial Informed and Guided Design of the Current Phase 3 EXPLORER-HCM Pivotal Trial SOUTH SAN FRANCISCO, Calif., April 30, 2019